Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Dec;18(1):15.
doi: 10.1186/s10194-017-0728-z. Epub 2017 Feb 4.

Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up

Affiliations
Clinical Trial

Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up

Licia Grazzi et al. J Headache Pain. 2017 Dec.

Abstract

Background: Chronic Migraine (CM) is a disabling condition, worsened when associated with Medication Overuse (MO). Mindfulness is an emerging technique, effective in different pain conditions, but it has yet to be explored for CM-MO. We report the results of a study assessing a one-year course of patients' status, with the hypothesis that the effectiveness of a mindfulness-based approach would be similar to that of conventional prophylactic treatments.

Methods: Patients with CM-MO (code 1.3 and 8.2 of the International Classification of Headache Disorders-3Beta) completed a withdrawal program in a day hospital setting. After withdrawal, patients were either treated with Prophylactic Medications (Med-Group), or participated in a Mindfulness-based Training (MT-Group). MT consisted of 6 weekly sessions of guided mindfulness, with patients invited to practice 7-10 min per day. Headache diaries, the headache impact test (HIT-6), the migraine disability assessment (MIDAS), state and trait anxiety (STAI Y1-Y2), and the Beck Depression Inventory (BDI) were administered before withdrawal and at each follow-up (3, 6, 12 after withdrawal) to patients from both groups. Outcome variables were analyzed in separate two-way mixed ANOVAs (Group: Mindfulness vs. Pharmacology x Time: Baseline, 3-, 6-, vs. 12-month follow-up).

Results: A total of 44 patients participated in the study, with the average age being 44.5, average headache frequency/month was 20.5, and average monthly medication intake was 18.4 pills. Data revealed a similar improvement over time in both groups for Headache Frequency (approximately 6-8 days reduction), use of Medication (approximately 7 intakes reduction), MIDAS, HIT-6 (but only for the MED-Group), and BDI; no changes on state and trait anxiety were found. Both groups revealed significant and equivalent improvement with respect to what has become a classical endpoint in this area of research, i.e. 50% or more reduction of headaches compared to baseline, and the majority of patients in each condition no longer satisfied current criteria for CM.

Conclusions: Taken as a whole, our results suggest that the longitudinal course of patients in the MT-Group, that were not prescribed medical prophylaxis, was substantially similar to that of patients who were administered medical prophylaxis.

Keywords: Chronic migraine; Medication overuse; Mindfulness; Pharmacological prophylaxis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of the study
Fig. 2
Fig. 2
Longitudinal course of headache frequency and consumption of medication. Note. Differences were always significant compared to baseline; no differences were found between the Med-Group and the MT-Group at any time point
Fig. 3
Fig. 3
Estimated marginal means for HIT-6 scores across time for Mindfulness and Pharmacology groups. Error bars represent standard errors

Similar articles

Cited by

References

    1. Global Burden of Disease Study 2013 Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. doi: 10.1016/S0140-6736(15)60692-4. - DOI - PMC - PubMed
    1. Steiner TJ, Stovner LJ, Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17:104. doi: 10.1186/s10194-016-0699-5. - DOI - PMC - PubMed
    1. Manack AN, Buse DC, Lipton RB. Chronic migraine: Epidemiology and disease burden. Curr Pain Headache Rep. 2011;15:70–78. doi: 10.1007/s11916-010-0157-z. - DOI - PubMed
    1. Giannini G, Favoni V, Bauleo S, Ferrante T, Pierangeli G, Albani F, Bacchi Reggiani ML, Baruzzi A, Cortelli P, Cevoli S. SPARTACUS: underdiagnosis of chronic daily headache in primary care. Neurol Sci. 2012;33:181–183. doi: 10.1007/s10072-012-1079-9. - DOI - PubMed
    1. Headache Classification Committee of the International Headache Society The International Classification of Headache Disorders, 3rd edition (beta version) Cephalalgia. 2013;33:629–808. doi: 10.1177/0333102413485658. - DOI - PubMed

Publication types